Three patents currently held, every record listed here
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2038. from the record
Of the 3 now held by other companies, 3 name Board of Regents the University of Texas System as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2038
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2020 to 2043.
US 10,875,920
Antibodies and Molecules That Immunospecifically Bind to BTN1A1 and the Therapeutic Uses Thereof
Jan 7, 2037
US 11,970,534
Antibodies and Molecules That Immunospecifically Bind to BTN1A1 and the Therapeutic Uses Thereof
Jul 19, 2038
US 11,542,331
Methods of Treating Cancer Using Antibodies and Molecules That Bind to BTN1A1 or BTN1A1-LIGANDS
Sep 2, 2038
US 12,215,151
Methods of Treating Cancer Using Antibodies and Molecules That Immunospecifically Bind to BTN1A1
Jun 10, 2039
US 12,059,474
Methods for Selecting Antibodies That Specifically Bind Glycosylated Immune Checkpoint Proteins
Dec 30, 2040
20252030203520402043
7 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Sep 2038 · High confidence
Also notable
Ends Apr 2043 · High confidence
Methods of Treating Cancer Using Antibodies and Molecules That Bind to BTN1A1 or BTN1A1-LIGANDS
US 11,542,331
A family of 18 related applications built on the 2023 grant. Protection runs to 2038.
Antibodies Specific to Glycosylated LAG3 and Methods of Use Thereof
US 12,595,304
Granted 2026. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Jan 2037 · High confidence
A family of 18 related applications built on the 2020 grant. Protection runs to 2037.
now held by Board of Regents, the University of Texas System
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods of Treating Cancer Using Antibodies and Molecules That Immunospecifically Bind to BTN1A1 | 2 in force | to Jun 2039 |
| Antibodies Specific to Glycosylated LAG3 and Methods of Use Thereof | 1 in force | to Apr 2043 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,542,331 | Methods of Treating Cancer Using Antibodies and Molecules That Bind to BTN1A1 or BTN1A1-LIGANDS In force · High confidence | In force | High confidence | |
| US 12,215,151 | Methods of Treating Cancer Using Antibodies and Molecules That Immunospecifically Bind to BTN1A1 In force · High confidence | In force | High confidence | |
| US 12,595,304 | Antibodies Specific to Glycosylated LAG3 and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 3 patents in force now held by others · 7 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.